Genotyping as a tool to predict adverse drug reactions

Current Topics in Medicinal Chemistry

Volumn 4, Issue 13, 2004, Pages 1411-1421

  Güzey, Cüneyt ^a   Spigset, Olav ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ARYLAMINE ACETYLTRANSFERASE; AZATHIOPRINE; CHOLINESTERASE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIAZEPAM; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; FLUOROURACIL; GLIPIZIDE; GLUCURONOSYLTRANSFERASE; HYDRALAZINE; IRINOTECAN; ISONIAZID; MERCAPTOPURINE; METOPROLOL; NEUROLEPTIC AGENT; PERHEXILINE; PHENYTOIN; SULFONAMIDE; SUXAMETHONIUM; THIOPURINE METHYLTRANSFERASE; THIORIDAZINE; TIMOLOL; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

APNEA; BLEEDING; BONE MARROW TOXICITY; BRADYCARDIA; CORRELATION ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENOTYPE; HEART PROARRHYTHMIA; HEREDITY; HUMAN; HYPOGLYCEMIA; LIVER TOXICITY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NEUROTOXICITY; PHARMACOGENETICS; PREDICTION; PROSPECTIVE STUDY; QT PROLONGATION; REVIEW; RISK FACTOR; RISK REDUCTION; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

EID: 4544354775     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387791     Document Type: Review

References (80)

1. Lazarou, J.; Pomeranz, B. H.; Corey, P. N. Incidence of Adverse Drug Reactions in Hospitalized Patients: Meta-Analysis of Prospective Studies. JAMA 1998, 279, 1200-1205.
2. Ernst, F. R.; Grizzle, A. J. Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness Model. J. Am. Pharm. Assoc. 2001, 41, 192-199.
3. Meyer, U. A. Pharmacogenetics and Adverse Drug Reactions. Lancet 2000, 356, 1667-1671.
4. Pirmohamed, M.; Park, B. K. Genetic Susceptibility to Adverse Drug Reactions. Trends Pharm. Sci. 2001, 22, 298-305.
5. Ingelman-Sundberg, M. Pharmacogenetics: An Opportunity for a Safer and More Efficient Pharmacotherapy. J. Intern. Med. 2001, 250, 186-200.
6. Güzey, C.; Spigset, O. Genotyping of Drug Targets. A Method to Predict Adverse Drug Reactions? Drug Saf. 2002, 25, 553-560.
7. Internet: www.imm.ki.se/cypalleles (accessed September 22, 2003)
8. Bertilsson, L. Geographical/Interracial Differences in Polymorphic Drug Oxidation. Current Status of Knowledge of Cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 1995, 29, 192-209.
9. Morgan, M. Y.; Reshef, R.; Shan, R. R.; Oates, N. S.; Smith, R. L.; Sherlock, S. Impaired Oxidation of Debrisoquine in Patients with Perhexilline Liver Injury. Gut 1984, 25, 1057-1064.
10. Arthur, H.; Dahl, M-L.; Siwers, B.; Sjöqvist, F. Polymorphic Drug Metabolism in Schizophrenic Patients with Tardive Dyskinesia. J. Clin. Psychopharmacol. 1995, 15, 211-216.
11. Andreassen, O. A.; MacEvan, T.; Gulbrandsen, A. K.; Me Creadie, R. G.; Steen, V. M. Non-Functional CYP2D6 Alleles and Risk for Neuroleptic-Induced Movement Disorders in Schizophrenic Patients. Psychopharmacology 1997, 131, 174-179.
12. Vandel, P.; Haffen, E.; Vandel, S.; Bonin, B.; Nezelof, S.; Broly, P.; Bizouard, P.; Dalery, J. Drug Extrapyramidal Side Effects. CYP2D6 Genotypes and Phenotypes. Eur. J. Clin. Pharmacol. 1999, 55, 659-665.
13. Ellingrod, V. L.; Schultz, S. K.; Arndt, S. Abnormal Movements and Tardive Dyskinesias in Smokers and Nonsmokers with Schizophrenia Genotyped for Cytochrome P-450 2D6. Pharmacotherapy 2002, 22, 1416-1419.
14. Smith, R. L. Polymorphic Metabolism of the β-Adrenoreceptor Blocking Drugs and its Clinical Significance. Eur. J. Clin. Pharmacol. 1985, 28 (suppl.), 77-84.
15. Wuttke, H.; Rau, T.; Heide, R.; Bergmann, K.; Bohm, M.; Weil, J.; Werner, D.; Eschenhagen, T. Increased Frequency of Cytochrome P450 2D6 Poor Metabolizers among Patients with Metoprolol-Associated Adverse Effects. Clin. Pharmacol. Ther. 2002, 72, 429-437.
16. Llerena, A.; Berecz, R.; de la Rubai, A.; Dorado, P. QTc Interval Lengthening is Related to CYP2D6 Hydroxylation Capacity and Plasma Concentration of Thioridazine in Humans. J. Psychopharmacol. 2002, 16, 361-364.
17. Eichelbaum, M.; Gross, A. S. The Genetic Polymorphism of Debrisoquine/Sparteine Metabolism - Clinical Aspects. Pharmacol. Ther. 1990, 46, 377-394.
18. Park, B. K.; Pirmohamed, M.; Kitteringham, N.R. The Role of Cytochrome P450 Enzymes in Hepatic and Extrahepatic Human Drug Toxicity. Pharmacol. Ther. 1995, 68, 385-424.
19. Dalen, P.; Frengell, C.; Dahl, M.-L.; Sjöqvist, F. Quick Onset of Severe Abdominal Pain after Codeine in an Ultrarapid Metabolizer of Debrisoquine. Ther. Drug Monit. 1997, 19, 543-544.
20. de Leon, J.; Dinsmore, L.; Wedlund, P. Adverse Drug Reactions to Oxycodone and Hydrocodone in CYP2D6 Ultrarapid Metabolizers. J. Clin. Psychopharmacol. 2003, 23, 420-421.
21. Kirchheiner, J.; Brøsen, K.; Dahl, M.-L.; Gram, L. F.; Kasper, S.; Roots, I.; Sjöqvist, F.; Spina, E.; Brockmöller, J. CYP2D6 and CYP2C19 Genotype-Based Dose Recommendations for Antidepressants: A First Step Towards Subpopulation-Specific Dosages. Acta Psychiatr. Scand. 2001, 104, 173-192.
22. Chou, W. H.; Yan, F.-X.; de Leon, J.; Barnhill, J.; Rogers, T.; Cronin, M; Pho, M.; Xiao, V.; Ryder, T. B.; Liu, W. W.; Teiling, C.; Wedlund, P. J. Extension of a Pilot Study: Impact of the Cytochrome P450 2D6 Polymorphism on Outcome and Costs Associated with Severe Mental Illness. J. Clin. Psychopharmacol. 2000, 2, 246-251.
23. Goldstein, J. A.; Clinical Relevance of Genetic Polymorphisms in the Human CYP2C9 Subfamily. Br. J. Clin. Pharmacol. 2001, 52, 349-355.
24. Aithal, G. P.; Day, C. P.; Kesteven, P. J.; Daly, A. K. Association of Polymorphisms in the Cytochrome P450 CYP2C9 with Warfarin Dose Requirement and the Risk of Bleeding Complications. Lancet 1999, 353, 717-719.
25. Higashi, M. K.; Veenstra, D. L.; Kondo, L. M.; Wittkowsky, A. K.; Srinouanprachanh, S. L.; Farin, F. M.; Rettie, A. E. Association between CYP2C9 Genetic Variations and Anticoagulation-Related Outcomes during Warfarin Therapy. JAMA 2002, 287, 1690-1698.
26. Ninomiya, H.; Mamiya K., Matsuo, S.; Ieiri, I.; Higuchi, S.; Tashiro, N. Genetic Polymorphism of the CYP2C9 Subfamily and Excessive Serum Phenytoin Concentration with Central Nervous System Intoxication. Ther. Drug Monit. 2000, 22, 230-232.
27. Brandolese, R.; Scordo, M. G.; Spina, E.; Gusella, M.; Padrini, R. Severe Phenytoin Intoxication in a Subject Homozygous for CYP2C9*3. Clin. Pharmacol. Ther. 2001, 70, 391-394.
28. Kidd, R. S.; Straughn, A. B.; Meyer, A. C.; Goldstein, J. A.; Dalton, J. T. Pharmacokinetics of Clorpheniramine, Phenytoin, Glipizide, and Nifedipine in an Individual Homozygous for the CYP2C9*3 Allele. Pharmacogenetics 1999, 9, 71-80.
29. Scordo, M. G.; Spina, E.; Romeo, P.; Bertilsson, L.; Johansson, I.; Sjöqvist, F. CYP2D6 Genotype and Antipsychotic-Induced Extrapyramidal Side Effects in Schizophrenic Patients. Eur. J. Clin. Pharmacol. 2000, 56, 679-683.
30. Carr, A.; Gross, A. S.; Hoskins, J. M.; Penny, R.; Cooper D. A. Acetylation Phenotype and Cutaneous Hypersensitivity to Trimethoprim-Sulphamethoxazole in HIV-Infected Patients. AIDS 1994, 8, 333-337.
31. Wolkenstein, P.; Carriere, V.; Charue, D.; Bastuji-Garin, S.; Revus, J.; Roujeau, J. C.; Beaune, P.; Bagot, M. A Slow Acetylator Phenotype is a Risk Factor for Suphonamide-Induced Toxical Epidermal Necrolysis and Stevens-Johnson Syndrome. Pharmacogenetics 1995, 5, 255-258.
32. Zieliska, E.; Niewiarowski, W.; Bodalski, J. The Arylamine N-Acetyltransferase (NAT2) Polymorphism and the Risk of Adverse Reactions to Co-Trimoxazole in Children. Eur. J. Clin. Pharmacol. 1998; 54: 779-785.
33. Tanaka, E.; Taniguchi, A.; Urano, W.; Nakajima, H.; Matsuda, Y.; Kitamura, Y.; Saito, M.; Yamanaka, H.; Saito, T.; Kamatani, N. Adverse Effects of Sulfasalazine in Patients with Rheumatoid Arthritis Are Associated with Diplotype Configuration at the N-Acetyltransferase 2 Gene. J. Rheumatol. 2002, 29, 2492-2499.
34. Ohno, M.; Yamaguchi, I.; Yamamoto, I.; Fukuda, T.; Yokota, S.; Maekura, R.; Ito, M.; Yamamoto, Y.; Ogura, T.; Maeda, K.; Komuta, K.; Igarashi, T.; Azuma, J. Slow N-Acetyltransterase 2 Genotype Affects the Incidence of Isoniazid and Rifampicin-Induced Hepatotoxicity. Int. J. Tuberc. Lung Dis. 2000; 4: 256-261.
35. Huang, Y. S.; Chem, H. D.; Su, W. J.; Wu, J. C.; Lai, S. L., Yang, S. Y.; Chang, F. Y.; Lee, S. D. Polymorphism of the N-Acetyltransferase 2 Gene as a Susceptibility Risk Factor for Antituberculosis Drug-Induced Hepatitis. Hepatology 2002, 35, 883-889.
36. de Wildt, S. N.; Kearns, G. L.; Leeder, J. S.; van den Anker J, N. Glucuronidation in Humans. Clin. Pharmacokinet. 1999, 36, 439-452.
37. Relling, M. V.; Dervieux, T. Pharmacogenetics and Cancer Therapy. Nature Rev. 2001, 1, 99-108.
38. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokohama, A.; Saitoh, S.; Shimokata, K., Hasegawa, Y. Polymorphisms of UDP-Glucuronosyltransferase Gene and Irinotecan Toxicity: A Pharmacogenetic Study. Cancer Res. 2000, 60, 6921-6926.
39. Tai, H.; Krynetski, E. Y.; Schuetz, E. G.; Yanishewski, Y.; Evans, W. E. Enhanced Proteolysis of Thiopurine S-Methyltransferase (TPMT) Encoded by Mutant Alleles in Humans (TPMT*3A, TPMT*2): Mechanisms for the Genetic Polymorphisms of TPMT Activity. Proc. Natl. Acad. Sci. USA 1997, 94, 6444-6449.
40. Evans, W. E.; Horner, M.; Chu, Y. Q.; Kalwinsky, D.; Roberts, W. M. Altered Mercaptopurine Metabolism, Toxic Effects, and Dosage Requirements in a Thiopurine Methyltransferase-Deficient Child with Acute Leukemia. J. Pediatr. 1991, 119, 985-989.
41. Schutz, E.; Gummert, J.; Mohr, F.; Oellerich, M. Azathioprine-Induced Myelosuppression in Thiopurine Methyltransferase-Deficient Heart Transplant Recipient. Lancet 1993, 341, 436.
42. Yates, C. R.; Krynetski, E. Y.; Loennechen, T.; Fessing, M. Y.; Tai, H. L.; Pui, C. H.; Relling, M. V.; Evans, W. E. Molecular Diagnosis of Thopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance. Ann. Intern. Med. 1997, 126, 608-614.
43. Relling, M. V.; Hancock, M. L.; Rivera, G. K. Sandlund, J. T.; Ribiero, R. C.; Krynetski, E. Y.; Pui, C. H.; Evans, W. E. Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Metyltransferase Gene Locus. J. Natl. Cancer Inst. 1999, 91, 2001-2008.
44. Evans, W. E.; Hon, Y. Y.; Bomgaars, L.; Coutre, S.; Holdsworth, M.; Janco, R.; Kalwinsky, D.; Keller, F.; Khatib, Z.; Margolin, J.; Murray, J.; Quinn, J.; Ravindranath, Y.; Ritchey, K.; Roberts, W.; Rogers, Z. R.; Schiff, D.; Steuber, C.; Tucci, F.; Kornegay, N.; Krynetski, E. Y.; Relling, M. V. Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity among Patients Intolerant to Mercaptopurine or Azathioprine. J. Clin. Oncol. 2001, 19, 2293-2301.
45. Gonzales, F. J.; Fernandez-Salguero, P. Diagnostic Analysis, Clinical Importance and Molecular Basis of Dihydropyrmidine Dehydrogenase Deficiency. Trends Pharmacol. Sci. 1995, 16, 325-327.
46. Wei, X.; McLeod, H. L.; McMurrough, J. Gonzales, F. J.; Fernandez-Salguero, P. Molecular Basis of the Human Dihydropyrmidine Dehydrogenase Deficiency and 5-Fluorouracil Toxicity. J. Clin. Invest. 1996, 98, 610-615.
47. Johnson, M. R.; Hageboutros, A; Wang, K.; High, L.; Smith, J. B.; Diasio, R. B. Life-Threatening Toxicity in a Patient with a Complete Dihydropyrmidine Dehydrogenase (DPD) Deficiency after Treatment with Topical 5-Fluorouracil. Clin. Cancer Res. 1999, 5, 2006-2011.
48. van Kuilenburg, A. B.; Muller, E. W.; Haasjes, J.; Meinsma, R.; Zoetekouw, L.; Waterham, H, R.; Baas, F.; Richel, D. J.; van Gennip, A. H. Lethal Outcome of a Patient with a Complete Dihydropyrmidine Dehydrogenase (DPD) Deficiency after Administration of 5-Fluorouracil: Frequency of the Common IVS14+1G>A Mutation Causing DPD Deficiency. Clin. Cancer Res. 2001, 7, 1149-1153.
49. Ulrich, C. M.; Yasui, Y.; Storb, R.; Schubert, M. M.; Wagner, J. L.; Bigler, J.; Ariail, K. S.; Keener, C. L.; Li, S.; Liu, H.; Farin, F. M., Potter, J. D. Pharmacogenetics of Methotrexate: Toxicity among Marrow Transplantation Patients Varies with the Methylenetrahydrofolate Reductase C677T Polymorphism. Blood 2001, 98, 231-234.
50. Evans, W. E. Differing Effects of Methylenetetrahydrofolate Reductase Single Nucleotide Polymorphisms on Methotrexate Efficacy and Toxicity in Rheumatoid Arthritis. Pharmacogenetics 2002, 12, 181-182.
51. Urano, W.; Taniguchi, A.; Yamanaka, H.; Tanaka, E.; Nakajima, H.; Matsuda, V.; Akama, H.; Kitaura, Y., Kamatani, N. Polymorphisms in the Methylenetetrahydrofolate Reductase Gene Were Associaated with Both the Efficacy and the Toxicity of Methotrexate Used for the Treatment of Rheumatoid Arthritis, as Evidenced by Single Locus and Haplotype Analyses. Pharmacogenetics 2002, 12, 183-190.
52. Levy, G. Predicting Effective Drug Concentrations for Individual Patients. Determinants of Pharmacodynamic Variability. Clin. Pharmacokinetics 1998, 34, 323-33.
53. Ackermann, M.J. The Long QT Syndrome. Pediatr. Rev. 1998, 19, 232-238.
54. Wang, Q.; Curran, M. F,., Splawski, I.; Burn, T. C.; Millholland, J. M.; van Raay, T. J.; Shen, J.; Timothy, K. W.; Vincent, G. M.; de Jager, T.; Schwartz, P. J.; Toubin, J. A.; Moss, A. J.; Atkinson, D. L.; Landes, G. M.; Connora, T. D.; Keating, M. T. Positional Cloning of a Novel Potassium Channel Gene: KVLQT1 Mutations Cause Cardiac Arrhythmias. Nat. Genet. 1996, 12, 17-23.
55. Curran, M. E.; Splawski, I.; Timothy, K. W.; Vincent, G. M.; Green, E. D.; Keating, M. T. A Molecular Basis For Cardiac Arrhythmia: HERG Mutations Cause Long QT Syndrome. Cell 1995, 80, 795-803.
56. Wang, Q.; Shen, J.; Splawski, I.; Atkinson, D.; Li, Z.; Robinson, J. L.; Moss, A. J.; Towbin, J. A.; Keating, M. T. SCN5A Mutations Cause an Inherited Cardiac Arrhythmia, Long QT Syndrome. Cell 1995, 80, 805-811.
57. Crouch, M.-A.; Limon, L.; Cassano, A. T. Clinical Relevance and Management of Drug-Related QT Interval Prolongation. Pharmacotherapy 2003, 23, 881-908.
58. Priori, S. G.; Napolitano, C.; Schwartz, P. J. Low Penetrance in the Long-QT Syndrome. Clinical Impact. Circulation 1999, 99, 529-533.
59. Steen, V. M.; Lovlie, R.; MacEvan, T.; McCreadie, R. G. Dopamine D3-Receptor Gene Variant and Susceptibility to Tardive Dyskinesia in Schizophrenia. Mol. Psychiatry 1997, 2, 139-145.
60. Basile, V. S.; Masellis, M.; Badri, F.; Paterson, A. D.; Meltzer, H. Y., Lieberman, J. A.; Potkin, S. G.; Macciardi, F.; Kennedy, J. L. Association of the MscI Polymorphisms of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia. Neuropsychopharmacology 1999, 21, 17-27.
61. Segman, R.; Neeman, T.; Heresco-Levy, U.; Finkel, B.; Karagichev, L.; Schlafman, M.; Dorevitch, A.; Yakir, A.; Lerner, A.; Shelevoy, A.; Lerer, B. Genotypic Association between the Dopamine D3 Receptor and Tardive Dyskinesia in Chronic Schizophrenia. Mol. Psychiatry 1999, 4, 247-253.
62. Segman, R. H.; Heresco-Levy, U.; Finkel, B.; Goltser, T.; Shalem, R.; Schlefamn, M.; Dorevitch, A.; Yakir, A.; Greenberg, D.; Lerner A.; Lerer, B. Association between the Serotonin 2A Receptor Gene and Tardive Dyskinesia in Chronic Schizophrenia. Mol. Psychiatry 2001, 6, 225-229.
63. gly Alleles to Susceptibility. Psychopharmacology 2000, 152, 408-413.
64. Gronert, G. A.; Mott, J.; Lee, J. Aetiology of Malignant Hyperthermia. Br. J. Anaesth. 1988, 60, 253-267.
65. MacLennan, D. H.; Otsu, K.; Fujii, J.; Zorzato, F.; Phillips, M. S.; O'Brien, P. J.; Archibald, A. L.; Britt, B. A.; Gillard, E. F.; Worton, R. G. The Role of the Skeletal Muscle Ryanodine Receptor Gene in Malignant Hyperthermia. Symp. Soc. Exp. Biol. 1992, 46, 189-201.
66. Urwyler, A.; Deufel, T.; McCarthy, T.; West, S. Guidelines for Molecular Genetic Detection of Susceptibility to Malignant Hyperthermia. Br. J. Anaesth. 2001, 86, 283-287.
67. Ørding, H. Diagnosis of Susceptibility to Malignant Hyperthermia in Man. Br. J. Anaesth. 1988, 60, 287-302.
68. Vandenbrouke, J. P.; Koster, T.; Briët, E.; Rietsma, P. H.; Bertina, R.M.; Rosendaal, F. R. Increased Risk of Venous Thrombosis in Oral-Contraceptive Users Who are Carriers of Factor V Leiden Mutation. Lancet 1994, 344, 1453-1457.
69. Martinelli, I.; Sacchi, E.; Landi, G.; Taioli, E.; Duca, F.; Mannucci, P. M. High Risk of Cerebral-Vein Thrombosis in Carriers of a Prothrombin-Gene Mutation in Users of Oral Contraceptives. N. Engl. J. Med. 1998, 338, 1793-1797.
70. Martinelli, I.; Taioli, E.; Bucciarelli, P.; Akhavan, S.; Mannucci, P. M. Interaction between the G20210A Mutation of the Prothrombin Gene and Oral Contraceptive Use in Deep Vein Thrombosis. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 700-703.
71. Vandenbrouke, J. P.; van der Meer, F. J. M.; Helmerhorst, F. M; Rosendaal, F. R. Factor V Leiden: Should We Screen Oral Contraceptive Users and Pregnant Women? BMJ 1996; 313: 1127-1130.
72. Pirmohamed, M.; Lin, K.; Chadwick, D.; Park, B. K. TNFalpha Promoter Region Gene Polymorphisms in Carbamazepine-Hypersensitive Patients. Neurology 2001, 56, 890-896.
73. Mallal, S.; Nolan, D.; Wilt C.; Masel G.; Martin, A. M.; Moore C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; James, I.; Christiansen, F. T. Association between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse Transcriptase Inhibitor Abacavir. Lancet 2002, 359, 727-732.
74. Hetherington, S.; Hughes, A. R.; Mosteller, M.; Shortino, D.; Baker, K. L.; Spreen, W.; Lai, E.; Davies, K.; Handley, A.; Dow, D. J.; Fling, M. E.; Stocum, M.; Bowmann, C.; Thurmond, L. M.; Roses, A. D. Genetic Variations In HLA-B Region and Hypersensitivity Reactions to Abacavir. Lancet 2002, 359, 1121-1122.
75. Spigset, O.; Hedenmalm, K.; Dahl, M.-L.; Wiholm, B-F.; Dahlqvist, R. Seizures and Myoclonus Associated with Antidepressant Treatment: Assessment of Potential Risk Factors, Including CYP2D6 and CYP2C19 Polymorphisms, and Treamtment with CYP2D6 Inhibitors. Acta Psychiatr. Scand. 1997, 96, 379-384.
76. Veronese, M. L.; Gillen, L. P.; Bruke, J. P.; Dorval, E. P.; Hauck, W.W.; Pequignot, E.; Waldman, S. A.; Greenberg, H. E. Exposure-Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice. J. Clin. Pharmacol. 2003, 43, 831-839.
77. Henderson, L.; Yue, Q. Y.; Bergquist, C.; Gerden, B.; Arlett, P. St John's Wort (Hypericum perforatum): Drug Interactions and Clinical Outcomes. Br. J. Clin. Pharmacol. 2002, 54, 349-356.
78. The International SNP Map Working Group. A Map of the Human Genome Sequence Variation Containing 1.42 Million Single Nucleotide Polymorphisms. Nature 2001, 409, 928-933.
79. Lechner, D.; Iathorp, G. M; Gut, I. G. Large-Scale Genotyping by Mass Spectrometry: Experience, Advances and Obstacles. Curr. Opin. Chem. Biol. 2002, 6, 31-38.
80. Jordan, B.; Charest, A.; Dowd, J. F.; Blumenstiel, J. P.; Yeh, R. F.; Osman, A.; Housman D. E.; Landers J. F. Genome Complexity Reduction for SNP Genotyping Analysis. Proc. Natl. Acad. Sci. USA 2002, 99, 2942-2947.